{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T20:59:56Z","timestamp":1787864396744,"version":"build-2784847793"},"reference-count":76,"publisher":"National Institute for Health and Care Research","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["NIHR136014"],"award-info":[{"award-number":["NIHR136014"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalslibrary.nihr.ac.uk"],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"\n Background<\/jats:title>\n Skin cancers are some of the most common types of cancer. Dermatology services receive about 1.2 million referrals a year, but only a small minority are confirmed skin cancer. Artificial intelligence may be helpful in the diagnosis of skin cancer by identifying lesions that are or are not cancerous.<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n To investigate the clinical and cost-effectiveness of two artificial intelligence technologies: DERM (Deep Ensemble for Recognition of Malignancy, Skin Analytics) and Moleanalyzer Pro (FotoFinder), as decision aids following a primary care referral.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n A rapid systematic review of evidence on the two technologies was conducted. A narrative synthesis was performed, with a meta-analysis of diagnostic accuracy data.<\/jats:p>\n Published and unpublished cost-effectiveness evidence on the named technologies, as well as other diagnostic technologies were reviewed. A conceptual model was developed that could form the basis of a full economic evaluation.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Four studies of DERM and two of Moleanalyzer Pro were subject to full synthesis. DERM had a sensitivity of 96.1% to detect any malignant lesion (95% confidence interval 95.4 to 96.8); at a specificity of 65.4% (95% confidence interval 64.7 to 66.1). For detecting benign lesions, the sensitivity was 71.5% (95% confidence interval 70.7 to 72.3) for a specificity of 86.2% (95% confidence interval 85.4 to 87.0). Moleanalyzer Pro had lower sensitivity, but higher specificity for detecting melanoma than face-to-face dermatologists.<\/jats:p>\n DERM might lead to around half of all patients being discharged without assessment by a dermatologist, but a small number of malignant lesions would be missed. Patient and clinical opinions showed substantial resistance to using artificial intelligence without any assessment of lesions by a dermatologist.<\/jats:p>\n No published assessments of the cost-effectiveness of the technologies were identified; three assessments related to skin cancer more broadly in a National Health Service setting were identified. These studies employed similar model structures, but the mechanism by which diagnostic accuracy influenced costs and health outcomes differed. An unpublished cost\u2013utility model was provided by Skin Analytics. Several issues with the modelling approach were identified, particularly the mechanisms by which value is driven and how diagnostic accuracy evidence was used.<\/jats:p>\n The conceptual model presents an alternative approach, which aligns more closely with the National Institute for Health and Care Excellence reference case and which more appropriately characterises the long-term consequences of basal cell carcinoma.<\/jats:p>\n <\/jats:sec>\n \n Limitations<\/jats:title>\n The rapid review approach meant that some relevant material may have been missed, and capacity for synthesis was limited. The proposed conceptual model does not capture non-cash benefits associated with demand on dermatologist time. An assessment of the likely budget impact and resource use could not be provided.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n DERM shows promising diagnostic accuracy for triage and diagnosis of suspicious cancer lesions in selected patients referred from primary care. Its impact on the diagnostic pathway and patient care is, however, uncertain. Moleanalyzer Pro shows promising accuracy for diagnosing melanoma, but its evidence base is limited.<\/jats:p>\n <\/jats:sec>\n \n Future work<\/jats:title>\n While artificial intelligence has the potential to be cost-effective for the identification of benign lesions, further research addressing the limitations in the diagnostic accuracy evidence is necessary. Without comparative evidence on the diagnostic accuracy of artificial intelligence technologies, their value will remain uncertain.<\/jats:p>\n <\/jats:sec>\n \n Study registration<\/jats:title>\n This study is registered as PROSPERO CRD42023475705.<\/jats:p>\n <\/jats:sec>\n \n Funding<\/jats:title>\n \n This award was funded by the National Institute for Health and Care Research (NIHR) Evidence Synthesis programme (NIHR award ref: NIHR136014) and is published in full in\n Health Technology Assessment<\/jats:italic>\n ; Vol. 30, No. 10. See the NIHR Funding and Awards website for further award information.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3310\/gjms0317","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T09:24:56Z","timestamp":1742203496000},"page":"1-96","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Artificial Intelligence technologies for assessing skin lesions for referral on the urgent suspected cancer pathway to detect benign lesions and reduce secondary care specialist appointments: early value assessment"],"prefix":"10.3310","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1932-3689","authenticated-orcid":true,"given":"Matthew","family":"Walton","sequence":"first","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, Heslington, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4569-5136","authenticated-orcid":true,"given":"Alexis","family":"Llewellyn","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, Heslington, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9759-2502","authenticated-orcid":true,"given":"Eleonora","family":"Uphoff","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, Heslington, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2131-782X","authenticated-orcid":true,"given":"Joseph","family":"Lord","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, Heslington, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2338-6869","authenticated-orcid":true,"given":"Melissa","family":"Harden","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, Heslington, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6962-2893","authenticated-orcid":true,"given":"Robert","family":"Hodgson","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, Heslington, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1999-8515","authenticated-orcid":true,"given":"Mark","family":"Simmonds","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, Heslington, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2026,2]]},"reference":[{"key":"key2026020918270300_ref2-bib2","volume-title":"Dermatology. GIRFT Programme National Specialty Report","author":"Levell","year":"2021"},{"key":"key2026020918270300_ref3-bib3","volume-title":"Clinical Knowledge Summary \u2013 Melanoma","year":"2022"},{"key":"key2026020918270300_ref4-bib4","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1002\/ski2.61","article-title":"An updated report on the incidence and epidemiological trends of keratinocyte cancers in the United Kingdom 2013\u20132018","volume":"1","author":"Kwiatkowska","year":"2021","journal-title":"Skin Health Dis"},{"key":"key2026020918270300_ref5-bib5","volume-title":"Clinical Knowledge Summary \u2013 Melanoma. How Should I Assess a Lesion?","year":"2022"},{"key":"key2026020918270300_ref6-bib6","volume-title":"Non-melanoma Skin Cancer"},{"key":"key2026020918270300_ref7-bib7","volume-title":"Clinical Knowledge Summary \u2013 Skin Cancers \u2013 Recognition and Referral","year":"2021"},{"key":"key2026020918270300_ref8-bib8","volume-title":"Faster Diagnosis"},{"key":"key2026020918270300_ref10-bib10","volume-title":"Melanoma","author":"Bhave","year":"2023"},{"key":"key2026020918270300_ref11-bib11","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.bjps.2010.07.006","article-title":"Revised UK guidelines for the management of cutaneous melanoma 2010","volume":"63","author":"Marsden","year":"2010","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"key2026020918270300_ref12-bib12","volume-title":"Improving Outcomes for People with Skin Tumours Including Melanoma. Cancer Service Guideline [CSG8]","author":"National Institute of Health and Care Excellence","year":"2010"},{"key":"key2026020918270300_ref13-bib13","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/bjd.19621","article-title":"British Association of Dermatologists guidelines for the management of people with cutaneous squamous cell carcinoma 2020","volume":"184","author":"Keohane","year":"2021","journal-title":"Br J Dermatol"},{"key":"key2026020918270300_ref16-bib16","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev"},{"key":"key2026020918270300_ref17-bib17","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1001\/jama.2017.19163","article-title":"Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA statement","volume":"319","author":"McInnes","year":"2018","journal-title":"JAMA"},{"key":"key2026020918270300_ref18-bib18","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","article-title":"PRESS peer review of electronic search strategies: 2015 guideline statement","volume":"75","author":"McGowan","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"key2026020918270300_ref19-bib19","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann Intern Med"},{"key":"key2026020918270300_ref20-bib20","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.7326\/M21-2234","article-title":"QUADAS-C: a tool for assessing risk of bias in comparative diagnostic accuracy studies","volume":"174","author":"Yang","year":"2021","journal-title":"Ann Intern Med"},{"key":"key2026020918270300_ref21-bib21","doi-asserted-by":"crossref","first-page":"l6890","DOI":"10.1136\/bmj.l6890","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ"},{"key":"key2026020918270300_ref22-bib22","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/hir.12252","article-title":"The Embase UK filter: validation of a geographic search filter to retrieve research about the UK from OVID Embase","volume":"36","author":"Ayiku","year":"2019","journal-title":"Health Info Libr J"},{"key":"key2026020918270300_ref23-bib23","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/hir.12187","article-title":"The MEDLINE UK filter: development and validation of a geographic search filter to retrieve research about the UK from OVID MEDLINE","volume":"34","author":"Ayiku","year":"2017","journal-title":"Health Info Libr J"},{"key":"key2026020918270300_ref24-bib24","doi-asserted-by":"crossref","first-page":"1288521","DOI":"10.3389\/fmed.2023.1288521","article-title":"Effectiveness of an image analyzing AI-based digital health technology to identify non-melanoma skin cancer and other skin lesions: results of the DERM-003 study","volume":"10","author":"Marsden","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"key2026020918270300_ref25-bib25","doi-asserted-by":"crossref","first-page":"1302363","DOI":"10.3389\/fmed.2024.1302363","article-title":"Accuracy of an artificial intelligence as a medical device as part of a UK-based skin cancer teledermatology service","volume":"11","author":"Marsden","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"key2026020918270300_ref26-bib26","doi-asserted-by":"crossref","first-page":"1264846","DOI":"10.3389\/fmed.2023.1264846","article-title":"Real-world post-deployment performance of a novel machine learning-based digital health technology for skin lesion assessment and suggestions for post-market surveillance","volume":"10","author":"Thomas","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"key2026020918270300_ref28-bib28","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jaad.2020.04.019","article-title":"The use of noninvasive imaging techniques in the diagnosis of melanoma: a prospective diagnostic accuracy study","volume":"85","author":"MacLellan","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"key2026020918270300_ref29-bib29","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1001\/jamadermatol.2023.0905","article-title":"Assessment of diagnostic performance of dermatologists cooperating with a convolutional neural network in a prospective clinical study: human with machine","volume":"159","author":"Winkler","year":"2023","journal-title":"JAMA Dermatol"},{"key":"key2026020918270300_ref30-bib30","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1111\/jdv.16165","article-title":"Diagnostic performance of a deep learning convolutional neural network in the differentiation of combined naevi and melanomas","volume":"34","author":"Fink","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key2026020918270300_ref31-bib31","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1093\/annonc\/mdy166","article-title":"Man against machine: diagnostic performance of a deep learning convolutional neural network for dermoscopic melanoma recognition in comparison to 58 dermatologists","volume":"29","author":"Haenssle","year":"2018","journal-title":"Ann Oncol"},{"key":"key2026020918270300_ref32-bib32","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.annonc.2019.10.013","article-title":"Man against machine reloaded: performance of a market-approved convolutional neural network in classifying a broad spectrum of skin lesions in comparison with 96 dermatologists working under less artificial conditions","volume":"31","author":"Haenssle","year":"2020","journal-title":"Ann Oncol"},{"key":"key2026020918270300_ref33-bib33","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ejca.2023.02.025","article-title":"Observational study investigating the level of support from a convolutional neural network in face and scalp lesions deemed diagnostically \u2018unclear\u2019 by dermatologists","volume":"185","author":"Kommoss","year":"2023","journal-title":"Eur J Cancer"},{"key":"key2026020918270300_ref34-bib34","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ejca.2020.04.043","article-title":"Past and present of computer-assisted dermoscopic diagnosis: performance of a conventional image analyser versus a convolutional neural network in a prospective data set of 1,981 skin lesions","volume":"135","author":"Sies","year":"2020","journal-title":"Eur J Cancer"},{"key":"key2026020918270300_ref35-bib35","first-page":"842","article-title":"Dark corner artefact and diagnostic performance of a market-approved neural network for skin cancer classification","volume":"19","author":"Sies","year":"2021","journal-title":"J Dtsch Dermatol Ges"},{"key":"key2026020918270300_ref36-bib36","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejca.2021.12.034","article-title":"Does sex matter? Analysis of sex-related differences in the diagnostic performance of a market-approved convolutional neural network for skin cancer detection","volume":"164","author":"Sies","year":"2022","journal-title":"Eur J Cancer"},{"key":"key2026020918270300_ref37-bib37","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2019.11.020","article-title":"Melanoma recognition by a deep learning convolutional neural network \u2013 performance in different melanoma subtypes and localisations","volume":"127","author":"Winkler","year":"2020","journal-title":"Eur J Cancer"},{"key":"key2026020918270300_ref38-bib38","first-page":"1178","article-title":"Collective human intelligence outperforms artificial intelligence in a skin lesion classification task","volume":"19","author":"Winkler","year":"2021","journal-title":"J Dtsch Dermatol Ges"},{"key":"key2026020918270300_ref39-bib39","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ejca.2020.12.010","article-title":"Association between different scale bars in dermoscopic images and diagnostic performance of a market-approved deep learning convolutional neural network for melanoma recognition","volume":"145","author":"Winkler","year":"2021","journal-title":"Eur J Cancer"},{"key":"key2026020918270300_ref40-bib40","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ejca.2021.10.030","article-title":"Monitoring patients at risk for melanoma: may convolutional neural networks replace the strategy of sequential digital dermoscopy?","volume":"160","author":"Winkler","year":"2022","journal-title":"Eur J Cancer"},{"key":"key2026020918270300_ref41-bib41","doi-asserted-by":"crossref","first-page":"e1913436","DOI":"10.1001\/jamanetworkopen.2019.13436","article-title":"Assessment of accuracy of an artificial intelligence algorithm to detect melanoma in images of skin lesions","volume":"2","author":"Phillips","year":"2019","journal-title":"JAMA Netw Open"},{"key":"key2026020918270300_ref42-bib42","first-page":"e2020011","article-title":"Detection of malignant melanoma using artificial intelligence: an observational study of diagnostic accuracy","volume":"10","author":"Phillips","year":"2020","journal-title":"Dermatol Pract Concept"},{"key":"key2026020918270300_ref43-bib43","first-page":"iv43","article-title":"Effectiveness of an image-analysing artificial intelligence-based digital health technology to diagnose nonmelanoma skin cancer and benign skin lesions","volume":"188","author":"Marsden","year":"2023","journal-title":"Br J Dermatol"},{"key":"key2026020918270300_ref44-bib44","volume-title":"Effectiveness of an image analysing AI-based digital health technology to diagnose non-melanoma skin cancer (NMSC) and benign skin lesions: results of the DERM-003 study (unpublished)","author":"Austin"},{"key":"key2026020918270300_ref45-bib45","doi-asserted-by":"crossref","first-page":"1259595","DOI":"10.3389\/fmed.2023.1259595","article-title":"Patient perspectives of artificial intelligence as a medical device in a skin cancer pathway","volume":"10","author":"Kawsar","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"key2026020918270300_ref48-bib48","volume-title":"Continued Improvement of Artificial Intelligence in Identifying Skin Cancer","author":"Andrew","year":"11\u201314 October 2023"},{"key":"key2026020918270300_ref50-bib50","volume-title":"Clinical Performance of an Artificial Intelligence as a Medical Device Deployed within an Urgent Suspected Skin Cancer Pathway (unpublished)","author":"Jenkins","year":"undated"},{"key":"key2026020918270300_ref51-bib51","first-page":"iv173","article-title":"Using artificial intelligence to triage skin cancer referrals: outcomes from a pilot study","volume":"188","author":"Baker","year":"2023","journal-title":"Br J Dermatol"},{"key":"key2026020918270300_ref52-bib52","volume-title":"Case Study: Artificial Intelligence Helping to Speed Up Skin Cancer Diagnosis in Leicester, Leicestershire, and Rutland Integrated Care System [unpublished]","year":"2023"},{"key":"key2026020918270300_ref53-bib53","volume-title":"Using Artificial Intelligence to Triage Skin Cancer Referrals: Outcomes from a Pilot Study (unpublished)","author":"Baker","year":"undated"},{"key":"key2026020918270300_ref54-bib54","volume-title":"DERM US and EU Validation Study.","author":"Skin Analytics Limited"},{"key":"key2026020918270300_ref55-bib55","volume-title":"A Study to Assess Whether an Artificial Intelligence (AI) Technology Can Be Used to Assess Images of Suspicious Skin Lesions to Determine the Likelihood of Skin Cancer; and Reduce the Number, and Cost Associated with, Biopsies of Skin Lesions in Primary Care","author":"Skin Analytics","year":"2019"},{"key":"key2026020918270300_ref56-bib56","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ejca.2020.11.034","article-title":"Skin lesions of face and scalp \u2013 classification by a market-approved convolutional neural network in comparison with 64 dermatologists","volume":"144","author":"Haenssle","year":"2021","journal-title":"Eur J Cancer"},{"key":"key2026020918270300_ref57-bib57","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1111\/jdv.14065","article-title":"Melanomas vs. nevi in high-risk patients under long-term monitoring with digital dermatoscopy: do melanomas and nevi already differ at baseline?","volume":"31","author":"Tschandl","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key2026020918270300_ref58-bib58","first-page":"CD013193","article-title":"Teledermatology for diagnosing skin cancer in adults","volume":"12","author":"Chuchu","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"key2026020918270300_ref59-bib59","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jval.2012.12.008","article-title":"The cost-effectiveness of a novel SIAscopic diagnostic aid for the management of pigmented skin lesions in primary care: a decision-analytic model","volume":"16","author":"Wilson","year":"2013","journal-title":"Value Health"},{"key":"key2026020918270300_ref60-bib60","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.jval.2017.11.009","article-title":"A modeling study of the cost-effectiveness of a risk-stratified surveillance program for melanoma in the United Kingdom","volume":"21","author":"Wilson","year":"2018","journal-title":"Value Health"},{"key":"key2026020918270300_ref61-bib61","first-page":"1","article-title":"VivaScope R 1500 and 3000 systems for detecting and monitoring skin lesions: a systematic review and economic evaluation","volume":"20","author":"Edwards","year":"2016","journal-title":"Health Technol Assess"},{"key":"key2026020918270300_ref62-bib62","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J Clin Oncol"},{"key":"key2026020918270300_ref63-bib63","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1001\/archderm.143.1.21","article-title":"Visual screening for malignant melanoma: a cost-effectiveness analysis","volume":"143","author":"Losina","year":"2007","journal-title":"Arch Dermatol"},{"key":"key2026020918270300_ref64-bib64","doi-asserted-by":"crossref","first-page":"P119","DOI":"10.1016\/j.jaad.2003.10.402","article-title":"Quality of life impact by melanoma as measured by utilities","volume":"50","author":"Hadley","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"key2026020918270300_ref65-bib65","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/bjd.12678","article-title":"Impact of in vivo reflectance confocal microscopy on the number needed to treat melanoma in doubtful lesions","volume":"170","author":"Alarcon","year":"2014","journal-title":"Br J Dermatol"},{"key":"key2026020918270300_ref66-bib66","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/bjd.13148","article-title":"Reflectance confocal microscopy as a second-level examination in skin oncology improves diagnostic accuracy and saves unnecessary excisions: a longitudinal prospective study","volume":"171","author":"Pellacani","year":"2014","journal-title":"Br J Dermatol"},{"key":"key2026020918270300_ref67-bib67","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jval.2017.10.009","article-title":"Expert elicitation of multinomial probabilities for decision-analytic modeling: an application to rates of disease progression in undiagnosed and untreated melanoma","volume":"21","author":"Wilson","year":"2018","journal-title":"Value Health"},{"key":"key2026020918270300_ref68-bib68","first-page":"bjgpopen20X","article-title":"Reducing vitamin D requests in a primary care cohort: a quality improvement study","volume":"4","author":"Veena","year":"2020","journal-title":"BJGP Open"},{"key":"key2026020918270300_ref69-bib69","volume-title":"An Economic Evaluation of Interventions to Improve the Uptake of Vitamin D Supplements in England and Wales","author":"Filby","year":"2014"},{"key":"key2026020918270300_ref70-bib70","doi-asserted-by":"crossref","first-page":"100468","DOI":"10.1016\/j.jcpo.2024.100468","article-title":"Skin in the game: the cost consequences of skin cancer diagnosis, treatment and care in Northern Ireland","volume":"39","author":"Ethna","year":"2024","journal-title":"J Cancer Policy"},{"key":"key2026020918270300_ref71-bib71","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1111\/bjd.13262","article-title":"Health-related quality of life in patients with melanoma expressed as utilities and disability weights","volume":"171","author":"Tromme","year":"2014","journal-title":"Br J Dermatol"},{"key":"key2026020918270300_ref72-bib72","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1177\/0272989X11401031","article-title":"Catalogue of EQ-5D scores for the United Kingdom","volume":"31","author":"Sullivan","year":"2011","journal-title":"Med Decis Making"},{"key":"key2026020918270300_ref73-bib73","volume-title":"StatPearls","author":"McDaniel","year":"2023"},{"key":"key2026020918270300_ref74-bib74","article-title":"Interventions for basal cell carcinoma of the skin","volume":"11","author":"Thomson","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"key2026020918270300_ref75-bib75","volume-title":"Basal Cell Carcinoma \u2013 An Overview","year":"2023"},{"key":"key2026020918270300_ref76-bib76","volume-title":"Basal Cell Carcinoma PIL","year":"2022"},{"key":"key2026020918270300_ref77-bib77","doi-asserted-by":"crossref","first-page":"220","DOI":"10.5114\/ada.2023.124795","article-title":"Growth rate of basal cell carcinoma: a meta-analysis and systematic review","volume":"40","author":"Fija\u0142kowska","year":"2023","journal-title":"Postepy Dermatol Alergol"},{"key":"key2026020918270300_ref78-bib78","volume-title":"Nivolumab for Treating Advanced (Unresectable or Metastatic) Melanoma [TA384]","author":"National Institute for Health and Care Excellence","year":"2016"},{"key":"key2026020918270300_ref79-bib79","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s40273-022-01218-7","article-title":"Estimating the relationship between EQ-5D-5L and EQ-5D-3L: results from a UK population study","volume":"41","author":"Hern\u00e1ndez Alava","year":"2023","journal-title":"PharmacoEconomics"},{"key":"key2026020918270300_ref80-bib80","volume-title":"Estimating EQ-5D by Age and Sex for the UK","author":"Hern\u00e1ndez Alava","year":"2022"},{"key":"key2026020918270300_ref81-bib81","volume-title":"Unit Costs of Health and Social Care 2022 Manual","author":"Jones","year":"2023"},{"key":"key2026020918270300_ref82-bib82","volume-title":"Drug Tariff","author":"NHS Prescription Services","year":"2023"},{"key":"key2026020918270300_ref83-bib83","volume-title":"Olaparib for Maintenance Treatment of BRCA Mutation-positive Advanced Ovarian, Fallopian Tube or Peritoneal Cancer After Response to First-line Platinum-based Chemotherapy (review of TA598) [ID6191]","author":"National Institute for Health and Care Excellence"},{"key":"key2026020918270300_ref84-bib84","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1001\/jamadermatol.2021.4915","article-title":"Checklist for evaluation of image-based artificial intelligence reports in dermatology: CLEAR derm consensus guidelines from the international skin imaging collaboration artificial intelligence working group","volume":"158","author":"Daneshjou","year":"2022","journal-title":"JAMA Dermatol"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2049957","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/sites\/journalslibrary\/files\/journal_data\/GJMS0317\/GJMS0317.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2049957","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T13:03:20Z","timestamp":1770642200000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/GJMS0317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":76,"alternative-id":["10.3310\/GJMS0317"],"URL":"https:\/\/doi.org\/10.3310\/gjms0317","relation":{},"ISSN":["2046-4924"],"issn-type":[{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"},{"value":"10-2023","name":"contractual_start_date","label":"contractual_start_date","group":{"name":"article_history","label":"Article History"}},{"value":"03-2024","name":"editorial_review_begun","label":"editorial review begun","group":{"name":"article_history","label":"Article History"}},{"value":"04-2025","name":"accepted_for_publication","label":"Accepted for publication","group":{"name":"article_history","label":"Article History"}}]}}